Opens in a new tab or window In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without ...

At 10.30am on a chilly Saturday the queue outside Manze’s pie-and-mash shop on Deptford High Street stretches 50 metres down the street. The restaurant has been a fixture of the south-east ...

Subscribe to our newsletter and stay updated on the latest developments and special offers!

Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales ...